ATE222124T1 - Chemische mittel - Google Patents
Chemische mittelInfo
- Publication number
- ATE222124T1 ATE222124T1 AT95941214T AT95941214T ATE222124T1 AT E222124 T1 ATE222124 T1 AT E222124T1 AT 95941214 T AT95941214 T AT 95941214T AT 95941214 T AT95941214 T AT 95941214T AT E222124 T1 ATE222124 T1 AT E222124T1
- Authority
- AT
- Austria
- Prior art keywords
- enzyme
- host
- prodrug
- component
- natural
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Developing Agents For Electrophotography (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9426192.2A GB9426192D0 (en) | 1994-12-23 | 1994-12-23 | Chemical compounds |
| GBGB9516810.0A GB9516810D0 (en) | 1995-08-16 | 1995-08-16 | Chemical compounds |
| PCT/GB1995/002991 WO1996020011A1 (en) | 1994-12-23 | 1995-12-21 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE222124T1 true ATE222124T1 (de) | 2002-08-15 |
Family
ID=26306259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95941214T ATE222124T1 (de) | 1994-12-23 | 1995-12-21 | Chemische mittel |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5985281A (https=) |
| EP (1) | EP0806964B1 (https=) |
| JP (1) | JP3805365B2 (https=) |
| KR (1) | KR100270650B1 (https=) |
| CN (1) | CN1095677C (https=) |
| AT (1) | ATE222124T1 (https=) |
| AU (1) | AU701916B2 (https=) |
| BR (1) | BR9510490B1 (https=) |
| CA (1) | CA2205091A1 (https=) |
| CZ (1) | CZ195297A3 (https=) |
| DE (1) | DE69527805T2 (https=) |
| ES (1) | ES2181805T3 (https=) |
| FI (1) | FI972683L (https=) |
| HU (1) | HUT77450A (https=) |
| IL (1) | IL116511A0 (https=) |
| MX (1) | MX9704575A (https=) |
| NO (1) | NO972882L (https=) |
| NZ (1) | NZ297529A (https=) |
| PL (1) | PL184031B1 (https=) |
| RU (1) | RU2189251C2 (https=) |
| SK (1) | SK80997A3 (https=) |
| TR (1) | TR199501654A2 (https=) |
| WO (1) | WO1996020011A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1193278A (zh) | 1995-08-16 | 1998-09-16 | 曾尼卡有限公司 | 化合物 |
| SG71046A1 (en) | 1996-10-10 | 2000-03-21 | Connector Systems Tech Nv | High density connector and method of manufacture |
| AU6000698A (en) * | 1997-02-14 | 1998-09-08 | Zeneca Limited | Proteins |
| GB9703201D0 (en) * | 1997-02-15 | 1997-04-02 | Zeneca Ltd | Chemical compounds |
| GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| JP4616991B2 (ja) * | 1998-09-18 | 2011-01-19 | イミューノメディクス、インコーポレイテッド | 化学療法剤の標的特異的な毒性を増加させるための方法および組成物 |
| US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
| US20040117863A1 (en) * | 1998-09-18 | 2004-06-17 | Edge Michael D. | Transgenically produced fusion proteins |
| EP1220864A4 (en) * | 1999-09-17 | 2003-05-21 | Genzyme Transgenics Corp | TRANSGENICALLY PRODUCED FUSION PROTEINS |
| US7067148B2 (en) | 2001-02-15 | 2006-06-27 | King Pharmaceutical Research & Development, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| BR0316643A (pt) * | 2002-11-27 | 2005-10-11 | Gtc Biotherapeutics Inc | Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos |
| US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| KR20080068089A (ko) * | 2005-10-21 | 2008-07-22 | 지티씨바이오쎄라퓨틱스,인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법 |
| US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| WO2007149827A2 (en) * | 2006-06-20 | 2007-12-27 | Janssen Pharmaceutica, N.V. | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| EP2077991B1 (en) * | 2006-10-03 | 2014-02-26 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| WO2009134389A2 (en) * | 2008-05-01 | 2009-11-05 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
| US10745492B1 (en) * | 2019-04-03 | 2020-08-18 | Ark Diagnostics, Inc. | Antibodies to symmetrically dimethylated arginine analytes and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5632990A (en) * | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| AU648015B2 (en) * | 1989-01-23 | 1994-04-14 | Akzo N.V. | Site specific in-vivo activation of therapeutic drugs |
| US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| AU674137B2 (en) * | 1992-01-30 | 1996-12-12 | Genzyme Limited | Chiral synthesis with modified enzymes |
| GB9323429D0 (en) * | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
| US5389537A (en) * | 1994-01-21 | 1995-02-14 | Wisconsin Alumni Research Foundation | Nuclease having altered specificity |
-
1995
- 1995-12-21 RU RU97112396/14A patent/RU2189251C2/ru not_active IP Right Cessation
- 1995-12-21 JP JP52028496A patent/JP3805365B2/ja not_active Expired - Fee Related
- 1995-12-21 CZ CZ971952A patent/CZ195297A3/cs unknown
- 1995-12-21 ES ES95941214T patent/ES2181805T3/es not_active Expired - Lifetime
- 1995-12-21 DE DE69527805T patent/DE69527805T2/de not_active Expired - Lifetime
- 1995-12-21 US US08/860,882 patent/US5985281A/en not_active Expired - Lifetime
- 1995-12-21 AT AT95941214T patent/ATE222124T1/de not_active IP Right Cessation
- 1995-12-21 WO PCT/GB1995/002991 patent/WO1996020011A1/en not_active Ceased
- 1995-12-21 CN CN95196986A patent/CN1095677C/zh not_active Expired - Fee Related
- 1995-12-21 AU AU42697/96A patent/AU701916B2/en not_active Ceased
- 1995-12-21 CA CA002205091A patent/CA2205091A1/en not_active Abandoned
- 1995-12-21 BR BRPI9510490-9A patent/BR9510490B1/pt not_active IP Right Cessation
- 1995-12-21 HU HU9702280A patent/HUT77450A/hu unknown
- 1995-12-21 KR KR1019970704250A patent/KR100270650B1/ko not_active Expired - Fee Related
- 1995-12-21 NZ NZ297529A patent/NZ297529A/xx not_active IP Right Cessation
- 1995-12-21 MX MX9704575A patent/MX9704575A/es not_active IP Right Cessation
- 1995-12-21 PL PL95320964A patent/PL184031B1/pl not_active IP Right Cessation
- 1995-12-21 FI FI972683A patent/FI972683L/fi unknown
- 1995-12-21 EP EP95941214A patent/EP0806964B1/en not_active Expired - Lifetime
- 1995-12-21 SK SK809-97A patent/SK80997A3/sk unknown
- 1995-12-22 TR TR95/01654A patent/TR199501654A2/xx unknown
- 1995-12-22 IL IL11651195A patent/IL116511A0/xx not_active IP Right Cessation
-
1997
- 1997-06-20 NO NO972882A patent/NO972882L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP3805365B2 (ja) | 2006-08-02 |
| RU2189251C2 (ru) | 2002-09-20 |
| IL116511A0 (en) | 1996-07-23 |
| HUT77450A (hu) | 1998-04-28 |
| CZ195297A3 (en) | 1997-12-17 |
| US5985281A (en) | 1999-11-16 |
| AU701916B2 (en) | 1999-02-11 |
| PL184031B1 (pl) | 2002-08-30 |
| JPH10511547A (ja) | 1998-11-10 |
| MX9704575A (es) | 1997-10-31 |
| NO972882D0 (no) | 1997-06-20 |
| FI972683A0 (fi) | 1997-06-19 |
| FI972683A7 (fi) | 1997-06-19 |
| KR100270650B1 (ko) | 2000-11-01 |
| PL320964A1 (en) | 1997-11-24 |
| TR199501654A2 (tr) | 1996-07-21 |
| NO972882L (no) | 1997-08-19 |
| WO1996020011A1 (en) | 1996-07-04 |
| FI972683L (fi) | 1997-06-19 |
| BR9510490B1 (pt) | 2010-10-05 |
| ES2181805T3 (es) | 2003-03-01 |
| CA2205091A1 (en) | 1996-07-04 |
| CN1095677C (zh) | 2002-12-11 |
| DE69527805D1 (de) | 2002-09-19 |
| BR9510490A (pt) | 1998-01-13 |
| TR199501654A3 (https=) | 1996-07-21 |
| NZ297529A (en) | 1999-07-29 |
| EP0806964B1 (en) | 2002-08-14 |
| CN1171054A (zh) | 1998-01-21 |
| DE69527805T2 (de) | 2003-04-24 |
| AU4269796A (en) | 1996-07-19 |
| SK80997A3 (en) | 1998-02-04 |
| EP0806964A1 (en) | 1997-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE222124T1 (de) | Chemische mittel | |
| BR0113491A (pt) | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. | |
| BR0210225A (pt) | Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante | |
| CY1106602T1 (el) | Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
| NO20014415D0 (no) | Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens | |
| IL105503A0 (en) | Active compounds | |
| IL130931A0 (en) | Small molecules useful in the treatment of inflammatory disease | |
| ATE297762T1 (de) | Peg-lhrh analog konjugate | |
| FI953529A0 (fi) | Rokotteita, jotka sisältävät gangliosidi-KLH-konjugaattia ja QS-21-ainetta | |
| BR0209254A (pt) | anticorpos de bloqueio cripto e usos dos mesmos | |
| OA07388A (fr) | Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués. | |
| DE69932733D1 (de) | Photosensitizer-konjugate zur zielrichtung von intrazellulare pathogene | |
| EP0859625A4 (en) | COMPOSITION AND METHOD FOR REINFORCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS | |
| BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
| ATE515258T1 (de) | Mukosales verabreichungssytem | |
| WO1999065517A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
| BR0313048A (pt) | Uso de alquilfosfocolinas em combinação com medicamentos antitumorais | |
| AU2002360350A1 (en) | Peptides that home to tumor lymphatic vasculature and methods of using same | |
| DK1161250T3 (da) | Immunstimulerende bakteriemembranfraktioner i cancerbehandling | |
| AU6182994A (en) | Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy | |
| IT1277926B1 (it) | Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire | |
| TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
| DE59712247D1 (de) | Mammakarzinom-assoziiertes gen | |
| CY1108790T1 (el) | Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου | |
| IT1274592B (it) | Composizione farmaceutica per la terapia tumorale contenente xenoantigeni |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |